TokenPost·
Ocugen Agrees to Sell OCU400 Rights in Australia, New Zealand and the ASEAN Region
The agreement would give Australian biopharma Celairis Therapeutics exclusive commercialization rights to the gene therapy candidate in those areas.
More news
- CoinspeakerIs Claude Bearish On Its Own Stock? Claude AI Predicts a Woeful Anthropic IPO
- TokenPostIranian Security Official Rejects U.S. Claims of Ongoing Talks, Qatar Meeting
- ProtosTether has about $4.8B in exposure to US stock markets
- TokenPostIran Says U.S. Claims of Ongoing Talks and Qatar Meetings Are Lies
- TokenPostZcash Rises 3.01% in One Hour to $1,005 on Binance Spot
- TokenPostPlume Affiliate Gains Broker-Dealer Status Ahead of Tokenized Asset Service